Omeros (OMER) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Omeros (OMER) has outperformed Savara (SVRA) over the past year, gaining 48.9% versus a loss of 13.4%. Over five years, SVRA leads with a +270.4% price change compared with +77.8% for OMER. Omeros is the larger company by market cap ($983.7 million vs $939.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OMER | SVRA |
|---|---|---|
| Share price | $13.21 | $4.26 |
| Market cap | $983.66M | $939.86M |
| 1-day change | -5.71% | -18.23% |
| YTD return | -23.11% | -29.35% |
| 1-year return | +48.93% | -13.41% |
| 5-year return | +77.79% | +270.43% |
| P/E ratio (TTM) | 15.92 | — |
| Forward P/E | 11.95 | — |
| EPS (TTM) | $0.83 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-3.35M | $-118.84M |
| 52-week high | $21.24 | $7.01 |
| 52-week low | $6.70 | $4.00 |
| Distance from 52-week high | -37.81% | -39.19% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +108.18% | +159.62% |
| Average volume | 1.36M | 2.79M |
| Shares outstanding | 74.46M | 220.62M |
| Employees | 175 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed SVRA by 62.3 percentage points over the past year.
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
OMER vs SVRA FAQ
Which is bigger, Omeros or Savara?
Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $939.86M for Savara (SVRA).
Which stock has performed better over the past year, OMER or SVRA?
OMER returned +48.93% over the past 12 months, compared with -13.41% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are Omeros and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.